Stock Chart

ELVN

$46.21 +0.81%
Score: 62.8 HOLD
LEAPs: SELL $55
i
LEAPs Option Signal

Type: SELL wallstreet
Strike: $55
Premium: $7.00
Expiry: Mar 19, 2027
Target: $57
Score: -71

LEAPs are long-term options (1+ year) with less time decay.
Pro
Screener
Vol: 0.64x (vs SPY: 0.6x | vs QQQ: 0.6x)
Volume Ratio Explained

Vol: Current volume vs 20-day average
vs SPY: Relative activity vs market
vs QQQ: Relative activity vs tech

Color Guide:
● Red (≥1.5x): High activity
● Yellow (≥1.2x): Above average
● Blue (≤0.7x): Low activity

Interpretation:
• vs SPY > 1: Stock-specific interest
• vs SPY < 1: Stock quiet vs market
Chart Pattern · as of Oct 01, 2026
Bear Pennant Bearish scenario quality 83/100
Setup invalidates on a close above $47.35 · pole −27% — no price target (measured-move targets failed our backtest for flags/pennants)
Historically breaks down 70% of the time (n=1,730). Measured-move targets failed our backtest — none shown.
Pattern detection is automated and probabilistic — a scenario map for levels, not a buy/sell signal. Rails, projected path and invalidation level are drawn on the chart below.
Technical Chart
CHART OVERLAYS
Active: 2
INDICATORS
TRENDLINES
OPTIONS FLOW
VOLUME & PRICE
OTHER

About ELVN - Enliven Therapeutics, Inc. Common Stock

Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.

Key Statistics

Market Cap $3B

This ELVN stock chart provides comprehensive technical analysis including candlestick patterns, volume profile analysis, and options open interest data. Track ELVN's price movements with trendlines, gamma walls, and key support/resistance levels.